{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["54(1)"],"submitter":["Hubel K"],"pubmed_abstract":["Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin's lymphoma patients eligible for high-dose chemotherapy with autologous stem cell transplantation. Mobilization is usually achieved with chemotherapy and/or cytokines, but plerixafor might be added in case of poor mobilization. Due to the high cost several institutions have developed their own management pathway to optimize use of plerixafor. Such models are however rarely generalizable; in a multi-center, European, non-interventional study, evaluating the impact of plerixafor in poor mobilizers, country specific differences in patient treatment and cost structure were obvious. For German centers, there was a non-significant reduction in the number of apheresis sessions ca"],"journal":["Bone marrow transplantation"],"pagination":["123-129"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6320344"],"repository":["biostudies-literature"],"pubmed_title":["Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs."],"pmcid":["PMC6320344"],"pubmed_authors":["Noppeney R","Kron A","Mohty M","Ostermann H","Milkovich G","Kron F","Hubel K","Glaß B"],"additional_accession":[]},"is_claimable":false,"name":"Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.","description":"Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin's lymphoma patients eligible for high-dose chemotherapy with autologous stem cell transplantation. Mobilization is usually achieved with chemotherapy and/or cytokines, but plerixafor might be added in case of poor mobilization. Due to the high cost several institutions have developed their own management pathway to optimize use of plerixafor. Such models are however rarely generalizable; in a multi-center, European, non-interventional study, evaluating the impact of plerixafor in poor mobilizers, country specific differences in patient treatment and cost structure were obvious. For German centers, there was a non-significant reduction in the number of apheresis sessions ca","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2026-04-29T16:04:54.343Z","creation":"2019-03-26T22:32:05Z"},"accession":"S-EPMC6320344","cross_references":{"pubmed":["29795422"],"doi":["10.1038/s41409-018-0228-z"]}}